KRAS is a gene that plays a very important role in the initiation and development of several types of cancer. In particular, 90% of human pancreatic cancers are due to KRAS mutations. KRAS is difficult to target directly and a promising therapeutic path is its indirect inactivation by targeting one of its Synthetic Lethal Partners (SLPs). A gene G is a Synthetic Lethal Partner of KRAS if the simultaneous perturbation of KRAS and G leads to cell death. In the past, efforts to identify KRAS SLPs with high-throughput RNAi screens have been performed. These studies have reported only few top-ranked SLPs. To our knowledge, these screens have never been considered in combination for further examination. This thesis employs integrative analysis ...
Background: KRAS mutations have been shown to play a key role in pancreatic cancer progression, but ...
Cancer remains the leading cause of mortality and morbidity in the world, with 19.3 million new diag...
Mutated KRAS protein is a pivotal tumor driver in pancreatic cancer. However, despite comprehensive ...
KRAS is a gene that plays a very important role in the initiation and development of several types o...
KRAS is a gene that plays a very important role in the initiation and development of several types o...
Mutated KRAS plays an important role in many cancers. Although targeting KRAS directly is difficult,...
Anti-Cancer drugs often affect both cancer and normal cells resulting in undesirable side effects. T...
The development of therapeutic agent against cancer is based on targeting key signaling proteins tha...
© 2021 Kimberly Jane MorganCancer is a major public health issue globally, ranking as the second mos...
Mutations in Kristen Rat Sarcoma viral oncogene (KRAS) are among the most frequent gain-of-function ...
SummaryAn alternative to therapeutic targeting of oncogenes is to perform “synthetic lethality” scre...
Targeting mutant KRAS signaling pathways continues to attract attention as a therapeutic strategy fo...
SummaryOncogenic mutations in the small GTPase Ras are highly prevalent in cancer, but an understand...
An alternative to therapeutic targeting of oncogenes is to perform “synthetic lethality” screens for...
Background: KRAS mutations have been shown to play a key role in pancreatic cancer progression, but ...
Background: KRAS mutations have been shown to play a key role in pancreatic cancer progression, but ...
Cancer remains the leading cause of mortality and morbidity in the world, with 19.3 million new diag...
Mutated KRAS protein is a pivotal tumor driver in pancreatic cancer. However, despite comprehensive ...
KRAS is a gene that plays a very important role in the initiation and development of several types o...
KRAS is a gene that plays a very important role in the initiation and development of several types o...
Mutated KRAS plays an important role in many cancers. Although targeting KRAS directly is difficult,...
Anti-Cancer drugs often affect both cancer and normal cells resulting in undesirable side effects. T...
The development of therapeutic agent against cancer is based on targeting key signaling proteins tha...
© 2021 Kimberly Jane MorganCancer is a major public health issue globally, ranking as the second mos...
Mutations in Kristen Rat Sarcoma viral oncogene (KRAS) are among the most frequent gain-of-function ...
SummaryAn alternative to therapeutic targeting of oncogenes is to perform “synthetic lethality” scre...
Targeting mutant KRAS signaling pathways continues to attract attention as a therapeutic strategy fo...
SummaryOncogenic mutations in the small GTPase Ras are highly prevalent in cancer, but an understand...
An alternative to therapeutic targeting of oncogenes is to perform “synthetic lethality” screens for...
Background: KRAS mutations have been shown to play a key role in pancreatic cancer progression, but ...
Background: KRAS mutations have been shown to play a key role in pancreatic cancer progression, but ...
Cancer remains the leading cause of mortality and morbidity in the world, with 19.3 million new diag...
Mutated KRAS protein is a pivotal tumor driver in pancreatic cancer. However, despite comprehensive ...